Sotera Health Q4 2024 Earnings Report
Key Takeaways
Sotera Health reported a decrease in net revenues for the fourth quarter of 2024, falling by 6.5% to $290 million. Net income also decreased to $12 million, or $0.04 per diluted share, compared to $39 million, or $0.14 per diluted share, in the same quarter of the previous year. Adjusted EBITDA saw a decrease of 8.3% to $153 million, and Adjusted EPS was $0.21, a decrease of $0.02 per diluted share.
Net revenues decreased by 6.5% to $290 million compared to Q4 2023.
Net income was $12 million, or $0.04 per diluted share, down from $39 million, or $0.14 per diluted share, in Q4 2023.
Adjusted EBITDA decreased by 8.3% to $153 million compared to the prior-year quarter.
Adjusted EPS was $0.21, a decrease of $0.02 per diluted share compared to Q4 2023.
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Forward Guidance
Sotera Health provided its full-year 2025 outlook, including net revenues growth in the range of 4.0% to 6.0% on a constant currency basis and Adjusted EPS in the range of $0.70 to $0.76.
Positive Outlook
- Net revenues growth in the range of 4.0% to 6.0%, on a constant currency basis.
- Adjusted EBITDA growth in the range of 4.5% to 6.5%, on a constant currency basis.
- Adjusted EPS in the range of $0.70 to $0.76.
- A weighted-average fully diluted share count in the range of 286 million to 287 million shares.
- Capital expenditures in the range of $190 million to $210 million.
Challenges Ahead
- Foreign currency headwind to net revenues of approximately 2.25%.
- Foreign currency headwind to Adjusted EBITDA of approximately 2.50%.
- Interest expense in the range of $155 million to $165 million.
- Tax rate applicable to Adjusted Net Income in the range of 33.0% to 35.0%.
- The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort.